CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the body’s natural production of growth hormone (GH) by activating GHRH receptors in the pituitary gland.
 This leads to increased GH secretion, which in turn elevates insulin-like growth factor-1 (IGF-1) levels, supporting various physiological processes.
 The peptide is designed to enhance stability and prolong biological activity, with its half-life extended to 6–8 days when modified with Drug Affinity Complex (DAC), allowing for less frequent dosing compared to the non-DAC version.
Key benefits of CJC-1295 include enhanced muscle growth and lean body mass through increased protein synthesis and muscle fiber regeneration.
 It supports fat metabolism by promoting lipolysis and preferential fat burning, aiding in body composition improvements and helping to reduce visceral and subcutaneous adipose tissue.
 The peptide also accelerates recovery from physical activity or injury by enhancing tissue repair, collagen synthesis, and wound healing.
 Additionally, it improves sleep quality by increasing slow-wave sleep and supporting better cortisol management, which contributes to improved energy and cognitive function.
CJC-1295 may also support metabolic health by improving insulin sensitivity and glucose metabolism, potentially benefiting individuals with metabolic dysfunction.
 It contributes to bone health by promoting osteoblast activity and bone matrix formation.
 In anti-aging and wellness contexts, it helps counteract age-related declines in GH, supporting vitality, skin tone, and overall well-being.
 Research indicates that CJC-1295 can increase GH levels by 200–1000%, with elevated production sustained for up to six days.
However, its use is associated with potential side effects such as mild injection site reactions, transient fluid retention, temporary changes in appetite or sleep patterns, and possible suppression of natural GH pulsatility with chronic use.
 Theoretical concerns include a potential risk of promoting tumor growth due to GH stimulation, particularly in individuals with active cancer or hormone-sensitive malignancies.
 Therefore, CJC-1295 is contraindicated in people with active cancer, uncontrolled diabetes, significant cardiovascular disease, or pituitary tumors.
 It is not FDA-approved for human use and is considered investigational, with clinical applications restricted to research or under medical supervision.